**Supplemental Figure 1. Geographic distribution of patients by visit method**
Geographic distribution of patients across (A) the United States, (B) the northeast and (C) the regional area. Red circles denote patients seen through in-person encounters, blue circles denote patients seen through telehealth encounters and green circles denote patients seen through both visit types. Random noise was introduced for patient privacy.

**Supplemental Figure 2. Diagnoses seen by visit method in 2019 and 2020**
Distribution of the 10 most frequent diagnoses aggregated by ICD-10 category. Error bars
indicate the 95% confidence interval of the proportion.

Supplemental Figure 3. Patient satisfaction survey results stratified by year
Note that survey results were not stratified by visit method. Not all questions were asked of all respondents. Wilcoxon tests were performed for each question. No correction for multiple testing was performed.

Supplemental Figure 4. Breadth of Initial Evaluation
(A) Breadth of the recommended initial evaluation stratified by modality. Breadth of particular testing was determined by consensus of the clinically trained authors and ranged from 1 for single gene tests to 5 for exome. (B) Same analysis as A but for testing actually completed.

Supplemental Figure 5. New molecular diagnostic rate stratified by initial evaluation type
Error bars indicate the 95% confidence interval of the proportion. We excluded participants with a pre-existing molecular diagnosis.